You are here

  • Home
  • Archive
  • Volume 48, Issue 1
  • Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial

Article Text

Article menu
Download PDFPDF
Nutrition
Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial
  1. B Danielea,
  2. F Perroneb,
  3. C Galloc,
  4. S Pignataa,
  5. S De Martinod,
  6. R De Vivoa,
  7. E Barlettaa,
  8. R Tambaroa,
  9. R Abbiatie,
  10. L D'Agostinod
  1. aDivisione di Oncologia Medica B, Istituto Nazionale Tumori, Napoli, Italy, bUfficio Sperimentazioni Cliniche Controllate, Istituto Nazionale Tumori, Napoli, Italy, cCattedra di Metodologia Epidemiologica Clinica, Seconda Università, Napoli, Italy, dDivisione di Gastroenterologia, Università Federico II, Napoli, Italy, eDirezione Medica Italia, Bracco SpA, Milano, Italy
  1. Dr B Daniele, Divisione di Oncologia Medica B, Istituto Nazionale Tumori, via M. Semmola, 80131 Napoli, Italy. bdaniele{at}sirio-oncology.it

Abstract

BACKGROUND 5-Fluorouracil (FU) in association with folinic acid (FA) is the most frequently used chemotherapeutic agent in colorectal cancer but it often causes diarrhoea. Animal and human studies suggest that glutamine stimulates intestinal mucosal growth.

AIM To determine if oral glutamine prevents changes in intestinal absorption (IA) and permeability (IP) induced by FU/FA.

METHODS Seventy chemotherapy naive patients with colorectal cancer were randomly assigned to oral glutamine (18 g/day) or placebo before the first cycle of FU (450 mg/m2) and FA (100 mg/m2) administered intravenously for five days. Treatment was continued for 15 days, starting five days before the beginning of chemotherapy. IA (d-xylose urinary excretion) and IP (cellobiose-mannitol test) were assessed at baseline and four and five days after the end of the first cycle of chemotherapy, respectively. Patients kept a daily record of diarrhoea, scored using the classification system of the National Cancer Institute (Bethesda, Maryland, USA). Duration of diarrhoea was recorded and the area under the curve (AUC) was calculated for each patient.

RESULTS Baseline patient characteristics and basal values of IP and IA tests were similar in the two arms. After one cycle of chemotherapy, the reduction in IA (d-xylose absorption) was more marked in the placebo arm (7.1% v 3.8%; p=0.02); reduction of IP to mannitol was higher in the placebo arm (9.2%v 4.5%; p=0.02); and urinary recovery of cellobiose was not different between the study arms (p=0.60). Accordingly, the cellobiose-mannitol ratio increased more in the placebo arm (0.037 v 0.012; p=0.04). Average AUC of diarrhoea (1.9 v 4.5; p=0.09) and average number of loperamide tablets taken (0.4v 2.6; p=0.002) were reduced in the glutamine arm.

CONCLUSIONS Glutamine reduces changes in IA and IP induced by FU and may have a protective effect on FU induced diarrhoea.

  • glutamine
  • 5-fluorouracil
  • colorectal cancer
  • randomised trial

  • Abbreviations used in this paper

    FU
    5-fluorouracil
    FA
    folinic acid
    IP
    intestinal permeability
    IA
    intestinal absorption
    AUC
    area under the curve
    PS
    performance status

    • https://doi.org/10.1136/gut.48.1.28

    Statistics from Altmetric.com

      Request Permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    • Abbreviations used in this paper

      FU
      5-fluorouracil
      FA
      folinic acid
      IP
      intestinal permeability
      IA
      intestinal absorption
      AUC
      area under the curve
      PS
      performance status
      • View Full Text